Athersys and Aspire Capital Fund end their relationship

The Cleveland biotechnology company said it will 'evaluate alternative financing options to support continuing operations' following an announcement of the termination of its $100 million equity purchase agreement with Aspire.

Related Keywords

Dan Camardo ,Williambj Lehmann ,Ivor Macleod ,John Harrington ,Exchange Commission ,Capital Fund ,Nasdaq ,Athersys Inc ,Aspire Capital Fund ,